Innate Pharma News

Innate Pharma Unveils Promising Cancer Therapies at EHA

TipRanksMay 15 07:30

Innate Pharma's Four Abstracts With Innate's Drug Candidates Accepted For The European Association Of Hematology 2024 Congress

Two abstracts on SAR443579 (IPH6101), ANKET platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancerTwo abstracts on IPH6501, Inna

BenzingaMay 15 01:08

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate's drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.

BusinesswireMay 15 00:00

Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)

TipRanksMay 14 20:50

Earnings Call Summary | Innate Pharma(IPHA.US) Q1 2024 Earnings Conference

The following is a summary of the Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript:Financial Performance:Innate Pharma has a firm cash status with about EUR115 million in cash as of the end

Futu NewsMay 14 14:03 · Conference Call

Innate Pharma S.A. Advances Oncology Pipeline

TipRanksMay 14 07:05

6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 14 05:10 · Announcements

Innate Pharma Reported Q1 Revenue Of €6.6M Down From €26M YoY; Cash Position Of €113.9M

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 t

BenzingaMay 14 01:49

Press Release: Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results -- First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral

Dow JonesMay 14 00:00

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an

BusinesswireMay 7 00:00

NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)

Yahoo FinanceApr 26 03:12

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)

TipRanksApr 17 03:10

Innate Pharma's NK Cell Engager Enters Phase 2 Trials

TipRanksApr 15 20:00

Innate Pharma Announces Upcoming Annual General Meeting

Innate Pharma S.A., a clinical-stage biotechnology company, has announced its Annual General Meeting (AGM) scheduled for May 23, 2024, at its Marseille headquarters. Shareholders are invited to participate in the AGM and a guided tour of the company’s laboratories, with preparatory documents available on Innate’s website.

TipRanksApr 15 20:00

Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio

Yahoo FinanceApr 15 09:07

Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients

Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients

BenzingaApr 15 00:47

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de

BusinesswireApr 15 00:00

HC Wainwright & Co. : The Innate Pharma (IPHA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $11.50.

HC Wainwright & Co. : The Innate Pharma (IPHA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $11.50.

Zhitong FinanceApr 11 06:40

Innate Pharma: A Strong Buy on IPH45's Promising Data and Solid Financial Projections

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report) and keeping the price target at $11.50.

TipRanksApr 11 05:27

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy

Yahoo FinanceApr 10 11:00